Sugi Predict

Sugi Predict / Compounds / SCHEMBL349527

SCHEMBL349527

SCHEMBL349527

CC(C)(C)NS(=O)(=O)c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.66
▸ SMN1; SMN2 Q16637 3/20 0.66
▸ MEN1 O00255 2/20 0.66
▸ LMNA P02545 2/20 0.66
▸ KMT2A Q03164 2/20 0.66
▸ KDM4E B2RXH2 1/20 0.66
▸ NPC1 O15118 1/20 0.66
▸ HPGD P15428 1/20 0.66
▸ RAB9A P51151 1/20 0.66
▸ ALDH1A1 P00352 5/20 0.58
▸ PARG Q86W56 1/20 0.58
▸ CYP3A4 P08684 2/20 0.53
▸ CYP2C9 P11712 2/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ CA1 P00915 1/20 0.52
▸ CA2 P00918 1/20 0.52
▸ MMP1 P03956 1/20 0.52
▸ MMP2 P08253 1/20 0.52
▸ MMP9 P14780 1/20 0.52
▸ MMP8 P22894 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4680184 0.92 MAPT (0.58) MAPTSMN1; SMN2MEN1LMNAKMT2A
Boric Acid SCHEMBL5885888 0.92 MAPT (0.58) MAPTSMN1; SMN2MEN1LMNAKMT2A
SCHEMBL27802067 0.88 ALDH1A1 (0.56) MAPTSMN1; SMN2MEN1LMNAKMT2A
Trifluoroacetic Acid SCHEMBL29634285 0.87 MAPT (0.53) MAPTSMN1; SMN2MEN1LMNAKMT2A
SCHEMBL29446088 0.86 SMN1; SMN2 (0.56) MAPTSMN1; SMN2MEN1LMNAKMT2A
SCHEMBL28783847 0.83 MAPT (0.67) MAPTSMN1; SMN2MEN1LMNAKMT2A
SCHEMBL20988466 0.83 PGR (0.56) MAPTSMN1; SMN2LMNAKDM4EHPGD
SCHEMBL7895365 0.82 MEN1 (0.54) MAPTSMN1; SMN2MEN1LMNAKMT2A
SCHEMBL2803354 0.81 NSD2 (0.58) MAPTSMN1; SMN2MEN1LMNAKMT2A
SCHEMBL6903823 0.81 NR3C2 (0.53) MAPTSMN1; SMN2MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107459471-B Synthesis method of N-tert-butyl benzene sulfonamide 常州南京大学高新技术研究院 2020-06-30 — — CN claimed
CN-108440856-A Dye-colored body and method for producing same 谦华科技股份有限公司 2018-08-24 — — CN claimed
CN-105344375-B A kind of L-PROLINE organic micromolecule catalyst and its preparation and application 北京化工大学 2018-06-26 — — CN claimed
CN-108002732-A A kind of preparation method to tert-butyl benzene sulfonamide type concrete foamer 陈良培 2018-05-08 — — CN claimed
CN-107459471-A A kind of synthetic method of N tert-butyl benzenes sulfonamide 常州南京大学高新技术研究院 2017-12-12 — — CN claimed
US-9790321-B2 Heat resistant polyethylene terephthalate and a process for the preparation of the same ESTER INDUSTRIES LIMITED (IN) 2017-10-17 — — US claimed
EP-3218357-A1 3,4-DIAMINOBENZENESULFONAMIDE DERIVATIVES FOR INHIBITING CELL DEATH VIB vzw (BE) 2017-09-20 — — EP claimed
CN-103626742-B Bi-aryl meta-pyrimidine inhibitors of kinases 塔格根公司 2017-04-26 — — CN claimed
US-20160168321-A1 HEAT RESISTANT POLYETHYLENE TEREPHTHALATE AND A PROCESS FOR THE PREPARATION OF THE SAME ESTER INDUSTRIES LIMITED (IN) 2016-06-16 — — US claimed
WO-2016075330-A1 3,4-DIAMINOBENZENESULFONAMIDE DERIVATIVES FOR INHIBITING CELL DEATH VIB VZW (BE) 2016-05-19 — — WO claimed
CN-103012221-A Preparation method of benzene sulfonic amide derivatives UNIV ZHEJIANG 2013-04-03 — — CN claimed
US-8354407-B2 2-anilino-4-(heterocyclic)amino-pyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-15 — — US claimed
US-20110245225-A1 QUINAZOLINAMIDE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTING (DE) 2011-10-06 — — US claimed
US-20090227586-A1 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-10 — — US claimed
US-20070293494-A1 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines DJUNG JANE F 2007-12-20 — — US claimed
EP-1569932-A1 AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 Pharmacia Corporation (US) 2005-09-07 — — EP claimed
WO-2004055015-A1 AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 PHARMACIA CORPORATION (US) 2004-07-01 — — WO claimed
EP-0437177-B1 Process for the preparation of phenylsulfonamides CIBA GEIGY AG (CH) 1994-07-20 — — EP claimed
US-5087749-A PROCESS FOR THE PREPARATION OF PHENYLSULFONAMIDES CIBA-GEIGY CORPORATION (US) 1992-02-11 — — US claimed
EP-0437177-A1 Process for the preparation of phenylsulfonamides CIBA-GEIGY AG (CH) 1991-07-17 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293494-A1 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines PRKCA, PRKCG, PRKCH MAPT 3010/4885SMN1; SMN2 3836/4885MEN1 4783/4885
US-20090227586-A1 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES PRKCA, PRKCG, PRKCH MAPT 3010/4885SMN1; SMN2 3836/4885MEN1 4783/4885
US-20110245225-A1 QUINAZOLINAMIDE DERIVATIVES HSP90AB1, HSP90AA1, HSP90B1 MAPT 1533/4885SMN1; SMN2 3231/4885MEN1 4499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.